GSK3B and cancer: Considering that numerous studies have highlighted CXCR4’s role in inhibiting β-catenin degradation through the AKT/GSK-3β pathway, triggering intracellular β-catenin accumulation, Wnt pathway activation, and fostering cancer invasion and metastasis [30–32], we examined CXCR4 as a potential downstream target of PCDHGA9.